If you supply medicinal cannabis in Australia, regulatory compliance is not optional. TGA medicinal cannabis regulation covers how products are imported, manufactured, controlled, and lawfully supplied, especially where products are not included in the ARTG. The challenge is that compliance spans multiple areas, including quality standards, documentation, and controlled communications.
This article explains the current requirements at a practical level, so suppliers and distributors can reduce compliance risk and improve information accuracy.
In Australia, regulators generally classify medicinal cannabis products as prescription medicines, and the law prohibits advertising them to the public. Moreover, many products supplied through medicinal cannabis pathways remain unapproved and are not entered on the ARTG. Accordingly, the TGA advises that it has not assessed these unapproved products for safety, quality or efficacy.
For suppliers, this regulatory environment places a clear emphasis on compliance. As a result, suppliers must follow lawful supply pathways and ensure that all product information remains accurate, carefully controlled and appropriate for its intended audience.
A practical way to approach medicinal cannabis supplier compliance is to separate “market entry” from “ongoing obligations”:
This approach supports cannabis supply chain regulation in Australia’s expectations by ensuring accountability, documentation, and controlled supply processes are embedded from the start.
Quality requirements are a core pillar of TGA medicinal cannabis regulation. The TGA guidance explains that unapproved medicinal cannabis products imported into, supplied in, or manufactured in Australia must conform with TGO 93, which sets minimum quality requirements for medicinal cannabis products.
For suppliers, practical obligations usually include:
Because TGO 93 is a defined standard and the TGA publishes guidance for sponsors and manufacturers, suppliers should treat TGO 93 conformance as a “non-negotiable” governance requirement.
TGA guidance for importing, manufacturing, and supplying medicinal cannabis emphasises supplier responsibilities for compliant supply and supporting documentation. Therapeutic Goods Administration (TGA)+1
From a day-to-day compliance perspective, strong documentation standards usually include:
This supports medicinal cannabis regulatory compliance by ensuring you can evidence lawful supply and information integrity when requested.
One of the most common operational risks in regulated supply chains is information drift, pricing, pack sizes, availability, or compliance attributes getting out of date across multiple channels. For suppliers, this becomes an information governance problem, not a marketing problem.
A medicinal cannabis product database that is restricted to verified clinicians can help maintain cannabis product information consistency by enabling:
Clinician-only systems (for example, The Compendium) are particularly relevant where the objective is information accuracy rather than public promotion. (For internal linking, reference your relevant pages on The Compendium site, such as your “How it works” and “For suppliers” pages.)
Public content should remain educational and non-promotional. The TGA states that medicinal cannabis products are generally prescription medicines and public advertising is prohibited.
For low-risk public publishing, keep content focused on:
A low-risk approach to TGA medicinal cannabis regulation in Australia prioritises lawful supply governance, TGO 93 conformance and disciplined documentation. At the same time, it supports accurate product information by distributing it through controlled, clinician-only channels.
Ultimately, this approach aims to achieve operational reliability and regulatory compliance, rather than public promotion. Accordingly, if you are reviewing how to manage ongoing updates and data governance at scale, it may be worth exploring how clinician-only databases such as The Compendium help suppliers maintain current, version-controlled product information within a secure, access-controlled environment.
“*” indicates required fields
PRIVACY COLLECTION NOTICE
This Privacy Collection Notice describes how PHENIX HEALTH PTY LTD (ABN 22 607 822 266) (we, us or our) collects and handles your personal information when you make an enquiry with us. We collect personal information from you so that we can respond to your enquiry and for related purposes set out in our Privacy Policy, available on our website (or on request).
We may disclose this personal information to third parties, including our personnel, related entities, any third parties engaged by us and acting on our behalf and as otherwise set out in our Privacy Policy.
We store personal information in Australia. Where we disclose your personal information to third parties, those third parties may store, transfer or access personal information outside of Australia.
If you do not provide your personal information to us, it may affect our ability to do business with you.
Please see our Privacy Policy for more information about how we collect, store, use and disclose your personal information, including details about overseas disclosure, access, correction, how you can make a privacy-related complaint and our complaint-handling process.
If you have questions about our privacy practices, please contact us by email at: info@thecompendium.health. By providing your personal information to us, you agree to the collection, use, storage and disclosure of that information as described in this privacy collection notice.
